Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; all bio-pharmaceutical related provisions; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP and supply chain.
Duration: October 1, 2012
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Homeland Security
Spending: about $1,510,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John Green Dep Chief of Staff/Leg Aide, Senator Trent Lott
Stewart Hall Legislative Director, Senator Richard Shelby
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Matt Wise LegDirector/LegAide, Rep.Mary Fallin; LC, Sen.Conrad Burns
Steve Tilton HCRPolCoor/SenPolAdvr:ENG/CommBilirakis
Todd M. Weiss PolAdv,Hutchinson;LA/LD,Santorum;Staff,IntlRel
Anne W. Brady Deputy Chief of Staff, Rep. Mark Schauer
Jake Perry Legislative Aide, Sen. Harry Reid
Elizabeth Hart CoS,Cong. John Carney;CoS/Dep CoS/LD,Cong. Melissa Bean;Sr. LA,Cong. Baron Hill
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Katherine Dapper Staff Assistant, Senator Patty Murray
Jason Gleason Chief of Staff/ Legislative Director, Rep. John Sarbanes; Legislative Director/ Legislative Asst/ Legislative Correspondent/ Staff Asst, Sen. Paul Sarbanes
Chris Miller Chief of Staff/Legislative Director, Rep. Dave Reichert; Senior Legislative Asst, Rep. Gary Miller; Legislative Asst, Rep. Jennifer Dunn; LC, Sen. Tim Hutchinson; Staff Asst, Sen. Gordon Smith
Salim Alameddin Legislative Asst/Legislative Aide, Rep. Will Hurd; Legislative Correspondent/Staff Asst, Sen. John Cornyn
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Thomas J. Lucas Legislative Assistant, Legislative Aide, Legislative Correspondent, Staff Assistant: Senator Joe Manchin III
Alex Gleason Legislative Assistant, Legislative Aide, Legislative Correspondent, Rep. Ed Royce; Intern, Rep. Aaron Schock
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
Mathew Lapinski n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on April 22.
Original Filing: 301575028.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
CMMI Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; all bio-pharmaceutical related provisions; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2023
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Jan. 20.
Original Filing: 301533722.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; all bio-pharmaceutical related provisions; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2023
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301514840.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act;
H.R.5378, Lower Costs, More Transparency Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, H.R.4368/S.2131; all bio-pharmaceutical related provisions; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on July 19, 2023.
Original Filing: 301484347.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; all bio-pharmaceutical related provisions; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2023
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301460883.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price cap, and international pharmaceutical supply chain;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
H.R.830, HELP Copays Act;
S.127, Pharmacy Benefit Manager Transparency Act of 2023;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301437269.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PDUFA Reauthorization; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation); H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); FY2023 Consolidated Appropriations Act (H.R.2617); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation.
Issues related to R&D tax credit; FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Issues related to WTO TRIPS Waiver Process.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413567.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8239, S.4661); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
FY2022 Budget Reconciliation (H.R.5376); issues related to international taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Issues related to WTO TRIPS Waiver Process.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2022
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301391899.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
FY2022 Budget Reconciliation (H.R.5376); issues related to international taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2022
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on April 19, 2022.
Original Filing: 301360030.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2023 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
FY2022 Budget Reconciliation (H.R.5376); issues related to international taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2021
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Jan. 19, 2022.
Original Filing: 301326920.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.4502); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); issues related to international taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on Oct. 19, 2021.
Original Filing: 301304958.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.4356/S.2599); H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.4502); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); issues related to international taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on July 18, 2021.
Original Filing: 301279093.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $40,000. The report was filed on April 19, 2021.
Original Filing: 301255858.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301237453.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; S.1895, Lower Health Care Costs Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610); FY2021 Consolidated Appropriations Act (H.R.7608); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260); all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 17, 2020.
Original Filing: 301212596.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies.
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.7610); FY2021 Consolidated Appropriations Act (H.R.7608); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; all bio-pharmaceutical related provisions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 18, 2020.
Original Filing: 301193301.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
Implementation of 21st Century Cures Act (P.L.114-255).
S.1895, Lower Health Care Costs Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6800, The Heroes Act.
H.R.1425, State Health Care Premium Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 18, 2020.
Original Filing: 301171951.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and the international pharmaceutical supply chain.
Implementation of 21st Century Cures Act (P.L.114-255).
S.1895, Lower Health Care Costs Act of 2019.
Education around COVID-19 therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121438.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure; H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94); Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 18, 2019.
Original Filing: 301071802.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure; Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301052860.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of 21st Century Cures Act (P.L.114-255).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure; Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to international trade.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 21, 2019.
Original Filing: 301032801.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, truthful non-misleading industry communications, drug pricing, and drug importation policy.
Implementation of 21st Century Cures Act (P.L.114-255).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6);
FY 2020 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 19, 2019.
Original Filing: 301010576.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, truthful non-misleading industry communications, drug pricing, and drug importation policy.
Implementation of 21st Century Cures Act (P.L.114-255).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of 2018.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990652.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, truthful non-misleading industry communications, drug pricing, and drug importation policy.
Implementation of 21st Century Cures Act (P.L.114-255).
Implementation of P.L.115-176, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300970162.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, truthful non-misleading industry communications, drug pricing, and drug importation policy;
Implementation of 21st Century Cures Act (P.L.114-255);
H.R.878, Trickett Wendler Right to Try Act of 2017/S.204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (P.L.115-176).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300952013.xml
Lobbying Issues
Implementation of 21st Century Cures Act (P.L.114-255).
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and truthful non-misleading industry communications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap, IPAB Repeal and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018), Medicare Part B reimbursement and CMS rule related to next generation sequencing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018;
H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96);
H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123);
H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141);
Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931515.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and truthful non-misleading industry communications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare program, IPAB repeal and Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes (P.L.115-90); H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes; H.R.1370, Further Additional Continuing Appropriations Act, 2018 (P.L.115-96); Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.1, Tax Cuts and Jobs Act (P.L.115-97); issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 18, 2017.
Original Filing: 300907859.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017 (P.L.115-52).
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and truthful non-misleading industry communications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare program, IPAB repeal and Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; Food and Drug Administration (FDA) related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891668.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act.
S.204/H.R.878, Trickett Wendler Right to Try Act of 2017.
H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
H.R.2430/S.934, FDA Reauthorization Act of 2017.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and the 340B Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300868906.xml
Lobbying Issues
Implementation of P.L.114-255, 21st Century Cures Act. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. H.R.1628, American Health Care Act of 2017. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and the 340B Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017/FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; S.Con.Res.3, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026; FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847927.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.34, 21st Century Cures Act (P.L.114-255). S.2912, Trickett Wendler Right to Try Act of 2016. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and the 340B Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; H.R.2028, Further Continuing and Security Assistance Appropriations Act, 2017 (P.L.114-254); FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 18, 2016.
Original Filing: 300830953.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and Senate HELP Innovation Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to cybersecurity and data breach legislation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 19, 2016.
Original Filing: 300815517.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148) and the Food and Drug Administration Safety and Innovation Act (P.L.112-144). H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and Senate HELP Innovation Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; issues related to Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017; FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300795035.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and Senate HELP Innovation Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid including Demonstration Programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY2017 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.Con.Res.125, Establishing the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026; FDA related issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.456, Cyber Threat Sharing Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, S.961/H.R.2205, Data Security Act of 2015; data security and cybersecurity issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 19, 2016.
Original Filing: 300775037.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). H.R.6, 21st Century Cures Act. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program and Senate HELP Innovation Project.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016; FDA issues. P.L.114-74, Bipartisan Budget Act of 2015. P.L.114-113, Consolidated Appropriations Act, 2016; various issues including health, tax and cybersecurity.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform. P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to tax extenders.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 16, 2015.
Original Filing: 300755652.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and H.R.6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. H.R.3049/S.1800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016; FDA issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 17, 2015.
Original Filing: 300739594.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and H.R.6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; FDA issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R.234, Cyber Intelligence Sharing and Protection Act, S.456, Cyber Threat Sharing Act of 2015, S.754, Cybersecurity Information Sharing Act of 2015, S.961/H.R.2205, Data Security Act of 2015, S.1158, Consumer Privacy Protection Act of 2015, S.177/H.R.1770, Data Security and Breach Notification Act of 2015, S.1027, Data Breach Notification and Punishing Cyber Criminals Act of 2015, H.R.1704, Personal Data Notification and Protection Act of 2015, H.R.1560, Protecting Cyber Networks Act, H.R.1731, National Cybersecurity Protection Advancement Act; cybersecurity issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300718951.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144). Issues related to health care, the Food and Drug Administration (FDA), oncology coverage and 21st Century Cures.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.CON.RES.27/S.CON.RES.11, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
FY2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations; FDA issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 16, 2015.
Original Filing: 300697383.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144).
Issues related to health care and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014; issues related to tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678120.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144).
Issues related to health care, mental health and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014, issues related to tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 18, 2014.
Original Filing: 300660929.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144).
Issues related to health care, mental health and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.4800/S.2389, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2260, EXPIRE Act of 2014, issues related to tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 17, 2014.
Original Filing: 300638586.xml
Lobbying Issues
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54), the Patient Protection and Affordable Care Act (P.L. 111-148) and the Food and Drug Administration Safety and Innovation Act (P.L. 112-144).
Issues related to health care, mental health and the Food and Drug Administration (FDA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; H.R.4302, Protecting Access to Medicare Act of 2014; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to H.R.3547, Continuing Appropriations Resolution, 2014 (P.L. 113-76).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 17, 2014.
Original Filing: 300617737.xml
Lobbying Issues
H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; S.957, Drug Supply Chain Security Act; S.959, Pharmaceutical Quality, Security, and Accountability Act; Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, mental health and the FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.2810, Medicare Patient Access and Quality Improvement Act of 2013; issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.J.RES.59, Continuing Appropriations Resolution, 2014.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Oct. 18, 2013.
Original Filing: 300598958.xml
Lobbying Issues
H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; S.957, Drug Supply Chain Security Act; S.959, Pharmaceutical Quality, Security, and Accountability Act; Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, mental health and the FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.J.RES.59, Continuing Appropriations Resolution, 2014.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on July 19, 2013.
Original Filing: 300577391.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, mental health and the FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on April 18, 2013.
Original Filing: 300554640.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, mental health and the FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Crossroads Strategies, LLC lobbied for Bristol-Myers Squibb , earning $30,000. The report was filed on Jan. 19, 2013.
Original Filing: 300535921.xml
Lobbying Issues
Issues related to the implementation of the Patient Protection and Affordable Care Act, FDASIA implementation, health care, mental health and the FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
Crossroads Strategies, LLC filed a lobbying registration on Oct. 7, 2012 to represent Bristol-Myers Squibb, effective Oct. 1, 2012.
Original Filing: 300504409.xml
Issue(s) they said they’d lobby about: Issues related to the implementation of the Patient Protection and Affordable Care Act, Prescription Drug User Fee Act reauthorization, health care, mental health, Medicare, Medicaid and the FDA. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...